Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
January 21, 2011 updated by: AstraZeneca
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
217
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Hospital sample
Description
Inclusion Criteria:
- Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluate Faslodex therapeutic strategy and treatment duration
Time Frame: At the end of the study
|
At the end of the study
|
|
Describe the characteristics of patients treated with Faslodex
Time Frame: At the end of the study
|
At the end of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alain FLINOIS, TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
May 20, 2008
First Submitted That Met QC Criteria
May 20, 2008
First Posted (Estimate)
May 21, 2008
Study Record Updates
Last Update Posted (Estimate)
January 24, 2011
Last Update Submitted That Met QC Criteria
January 21, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-OFR-FAS-2007/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.